Loading
Life sciences · Journal article
Frontiers in Immunology · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immune-checkpoint blockade has changed cancer therapy, yet durable responses remain limited by immune exclusion, myeloid suppression and metabolic adaptation within the tumor immune microenvironment. Ferroptosis, an iron-dependent form of lipid-peroxidation-driven regulated cell death, offers a mechanistic bridge between tumor metabolism and antitumor immunity. Ferroptotic tumor cells can release danger signals, oxidized lipid mediators and antigenic material that shape dendritic-cell activation, macrophage behavior, myeloid-derived suppressor cell function and CD8+ T-cell responses. Based on currently heterogeneous evidence, we propose a working model in which acute and spatially restricted tumor-cell ferroptosis may favor immune priming and checkpoint sensitivity, whereas persistent or broadly distributed lipid-peroxidation stress may impair effector immune cells and sustain suppressive states. This temporal-spatial distinction remains incompletely validated in directly comparable experimental systems. This review summarizes the biochemical foundations of ferroptosis, the immune signals released by ferroptotic cells, the reprogramming of innate and adaptive immune compartments, and the emerging use of ferroptosis inducers, nanomedicines and immune-checkpoint combinations. We also discuss biomarkers, in vivo monitoring and immune-cell-specific toxicity as key barriers to clinical translation. A central conclusion is that ferroptosis should be treated not as a monolithic tumoricidal modality, but as a microenvironment-specific immune remodeling process whose therapeutic value depends on timing, localization and preservation of antitumor immune function.